JP2009540842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009540842A5 JP2009540842A5 JP2009516907A JP2009516907A JP2009540842A5 JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5 JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mutated
- mutant
- immunotoxin
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600900 | 2006-07-03 | ||
| PCT/DK2007/050082 WO2008003327A2 (en) | 2006-07-03 | 2007-07-03 | Immunotoxins for the treatment of diseases related to cmv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009540842A JP2009540842A (ja) | 2009-11-26 |
| JP2009540842A5 true JP2009540842A5 (https=) | 2010-08-19 |
Family
ID=38739380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516907A Pending JP2009540842A (ja) | 2006-07-03 | 2007-07-03 | Ｃｍｖ感染に関連する疾患の治療のための免疫毒素 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8592554B2 (https=) |
| EP (1) | EP2038302B1 (https=) |
| JP (1) | JP2009540842A (https=) |
| CA (1) | CA2656992A1 (https=) |
| WO (1) | WO2008003327A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070394A1 (en) * | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US20220281933A1 (en) * | 2019-07-12 | 2022-09-08 | Københavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
| US20220324947A1 (en) * | 2019-08-05 | 2022-10-13 | Stichting Vu | Identification and Elimination of HCMV-Infected Cells |
| JP7668785B2 (ja) * | 2019-09-03 | 2025-04-25 | シンクリノ エーピーエス | 融合タンパク質およびその使用 |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| EP0876487B1 (en) * | 1996-01-24 | 2008-03-12 | Schering Corporation | Mammalian cx3c chemokine genes |
| EP1009757A1 (en) * | 1997-09-04 | 2000-06-21 | Gryphon Sciences | Modular protein libraries and methods of preparation |
| ES2205849T3 (es) * | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| WO2000011950A1 (en) * | 1998-08-31 | 2000-03-09 | Oregon Health Science University | Prevention of cell migration initiation with cmv us28 receptor antagonists |
| AU2001249194A1 (en) * | 2000-03-23 | 2001-10-03 | Phylomed Corporation | Immunokine composition and method |
| US20020192212A1 (en) * | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| US20050136033A9 (en) | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
| CN1768862A (zh) * | 2004-10-26 | 2006-05-10 | 北京诺思兰德生物技术有限责任公司 | 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白 |
-
2007
- 2007-07-03 EP EP07764502A patent/EP2038302B1/en not_active Not-in-force
- 2007-07-03 CA CA002656992A patent/CA2656992A1/en not_active Abandoned
- 2007-07-03 WO PCT/DK2007/050082 patent/WO2008003327A2/en not_active Ceased
- 2007-07-03 US US12/306,395 patent/US8592554B2/en not_active Expired - Fee Related
- 2007-07-03 JP JP2009516907A patent/JP2009540842A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW496870B (en) | Compositions methods for stimulating megakaryocyte growth and differentiation | |
| JP6345216B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| JP6499333B2 (ja) | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 | |
| KR101895047B1 (ko) | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 | |
| JP2009540842A5 (https=) | ||
| ES2319827T3 (es) | Proteinas quimericas especificas del receptor il-13, y sus usos. | |
| US10188703B2 (en) | Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist | |
| TWI423813B (zh) | 使用免疫球蛋白片段之長效β干擾素製劑 | |
| TWI795443B (zh) | Ｇｌｐ-２衍生物之長效接合物 | |
| CN1665933B (zh) | 用于治疗肿瘤的免疫缀合物 | |
| JP2017529059A5 (https=) | ||
| JP2007500236A5 (https=) | ||
| CN110092837B (zh) | Uti融合蛋白 | |
| WO2015070210A1 (en) | Epha3 and multi-valent targeting of tumors | |
| JP2001526242A5 (https=) | ||
| JP2022513209A (ja) | オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物 | |
| US11752216B2 (en) | Insulin analog complex with reduced affinity for insulin receptor and use thereof | |
| JP2022514835A (ja) | インスリン及びグルカゴンを含む薬学組成物 | |
| EP2229179B1 (en) | Sldlr in viral hepatitis | |
| JP7668785B2 (ja) | 融合タンパク質およびその使用 | |
| WO2010074082A1 (ja) | バソヒビン修飾体 | |
| JP2024503242A (ja) | 短腸症候群の予防又は治療のためのインスリン分泌ペプチドとｇｌｐ－２の併用療法 | |
| CN117964777A (zh) | 一种接近天然分子的多肽融合分子 | |
| CN113329752A (zh) | 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法 | |
| Nemati et al. | The Types and Applications of Peptibodies |